| 2018-DAVI-68178 | |
| Ebola and Marburg viruses are a filamentous RNA virus that causes severe hemorrhagic fevers. Recovery from these viruses relies fully on the patient's immune response, because currently, there is no FDA-approved vaccine or medicine available to the public yet. These viruses are deadly and there is a need for a vaccine or some type of medicine that can treat these viruses better than what is available now. Researchers at Purdue University have developed a potential drug treatment for virus infections including Ebola and Marburg. This technology relies on selective inhibition of virus entry by a chemotype that inhibits the host vacuolar-ATPase. This will allow for the inhibition of the viral cell. This technology also allows for the inhibition of a host protein which will be key in treating these two viruses, because protein is needed for the viruses to achieve infection and replication. This new technology could open the door for how Ebola and Marburg are treated. Advantages: -Inhibition of the viral cell -Inhibition of a host Potential Applications: -Viral entry -Antiviral agents |
|
|
|
|
Apr 6, 2021
CIP-Patent
United States
(None)
(None)
Sep 18, 2020
NATL-Patent
United States
(None)
(None)
Mar 18, 2019
PCT-Patent
WO
(None)
(None)
Mar 19, 2018
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |